Tomorrow I will estimate based on yet another US-centric study conducted in 680 centers in the US the $CYDY CD12 trial placebo arm mortality rate. Which will happen to fall below 27% again…stay tuned, this confirms every previous study I analyzed before, bad outcome anticipated 1/ Here it is. Today I will show once again based on yet another US research paper that $CYDY COVID CD12 trial will VERY PROBABLY be a failure like its previous CD10 trial

A large-scale COVID study across 65 US HOSPITALS allows us to demonstrate that $CYDY ’s placebo arm shall have a mortality not far from the 22% Leronimab+placebo combined mortality reported
Meaning, Leronlimab is no different than placebo
investorshub.advfn.com/boards/read_ms… A synthesis of our estimate of Cytodyn’s CD12 trial placebo arm - the research paper we used to estimate it is fully consistent with the 50+ papers we reviewed before - more details on Monday as previously announced
$CYDY

As promised, and after $CYDY corrected its erroneous eIND PR, I will discuss in this thread 3 topics:
1) Can its CD12 trial meet primary endpoint statistical significance?
2) Did the FDA obtain early access to trial data and why?
3) Questions for Cytodyn's wednesday conf. call 1) Can its CD12 trial meet primary endpoint statistical significance?

We know from $CYDY SEC documents the following facts about its CD12 trial (for severe/critical COVID patients):

$CYDY is making bad news hard to understand for its shareholders

Before the open on Monday I WILL PROVE that the FDA just excluded from eIND ALL THE INTUBATED PATIENTS from its CD12 trial

Eg even the 4 anecdotal patients from the paper co-written by its CEO below WOULD BE OUT

https://twitter.com/rossoscud/status/1344646492892622849

Remember when I correctly infered in Oct. based on cross-arms mortality data disclosed by $CYDY that CD12 trial would not be stopped for early efficacy?
With the proof above I will infer again with some maths that CD12 is heading toward failure for both severes and criticals